Nothing Special   »   [go: up one dir, main page]

CO6251325A2 - Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr) - Google Patents

Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr)

Info

Publication number
CO6251325A2
CO6251325A2 CO09144825A CO09144825A CO6251325A2 CO 6251325 A2 CO6251325 A2 CO 6251325A2 CO 09144825 A CO09144825 A CO 09144825A CO 09144825 A CO09144825 A CO 09144825A CO 6251325 A2 CO6251325 A2 CO 6251325A2
Authority
CO
Colombia
Prior art keywords
seq
human
variable region
sequence
chain variable
Prior art date
Application number
CO09144825A
Other languages
English (en)
Inventor
Liqun Dong
Marc Nasoff
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of CO6251325A2 publication Critical patent/CO6251325A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1.- Un anticuerpo aislado o una porción de enlace de antígeno del mismo, el cual comprende una secuencia de la región variable de cadena pesada de la SEQ ID NO: 7 o de la SEQ ID NO: 21. 2.- Un anticuerpo aislado o una porción de enlace de antígeno del mismo, el cual comprende una secuencia de la región variable de cadena pesada de la SEQ ID NO: 7, y una secuencia de la región variable de cadena ligera de la SEQ ID NO: 8, o una secuencia de la región variable de cadena pesada de la SEQ ID NO: 21, y una secuencia de la región variable de cadena ligera de la SEQ ID NO: 22. 3.- El anticuerpo de la reivindicación 2, el cual comprende CDRH1, H2 y H3 de las SEQ ID NOs: 1, 2, y 3, respectivamente, o de las SEQ ID NOs: 15, 16, y 17, respectivamente, o una secuencia de CDRL1, L2 y L3 de las SEQ ID NOs: 4, 5, y 6, respectivamente, o de las SEQ ID NOs: 18, 19, y 20, respectivamente. 4.- El anticuerpo de la reivindicación 2, el cual comprende las CDRH1, H2 y H3 de las SEQ ID Nos: 1, 2, y 3, respectivamente, o de las SEQ ID Nos: 15, 16, y 17, respectivamente, y una secuencia de CDRL1, L2, y L3 de las SEQ ID NOs: 4, 5, y 6, respectivamente, o de las SEQ ID NO: 18, 19, y 20, respectivamente. 5.- El anticuerpo de la reivindicación 2, el cual comprende una secuencia de aminoácidos de la región variable de cadena pesada que es cuando menos el 80 por ciento idéntica a la SEQ ID NO: 7, y una secuencia de aminoácidos de la región variable de cadena ligera que es cuando menos el 80 por ciento idéntica a la SEQ ID NO: 8, o que comprende una secuencia de aminoácidos de la región variable de cadena pesada que es cuando menos el 80 por ciento idéntica a la SEQ ID NO: 21, y una secuencia de aminoácidos de la región variable de cadena ligera que es cuando menos el 80 por ciento idéntica a la SEQ ID NO: 22. 6.- El anticuerpo de la reivindicación 2, el cual es un anticuerpo quimérico.
CO09144825A 2007-06-20 2009-12-17 Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr) CO6251325A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94520507P 2007-06-20 2007-06-20

Publications (1)

Publication Number Publication Date
CO6251325A2 true CO6251325A2 (es) 2011-02-21

Family

ID=39846944

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09144825A CO6251325A2 (es) 2007-06-20 2009-12-17 Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr)

Country Status (20)

Country Link
US (1) US8101182B2 (es)
EP (1) EP2170957A1 (es)
JP (1) JP2010530233A (es)
KR (1) KR20100034015A (es)
CN (1) CN102027012A (es)
AR (1) AR067045A1 (es)
AU (1) AU2008265128A1 (es)
BR (1) BRPI0813725A2 (es)
CA (1) CA2691157A1 (es)
CL (1) CL2008001826A1 (es)
CO (1) CO6251325A2 (es)
CR (1) CR11152A (es)
EA (1) EA201000006A1 (es)
EC (1) ECSP099812A (es)
IL (1) IL202573A0 (es)
PE (1) PE20090768A1 (es)
TN (1) TN2009000529A1 (es)
TW (1) TW200918557A (es)
WO (1) WO2008155365A1 (es)
ZA (1) ZA200908711B (es)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE362534T2 (de) 1998-11-13 2007-06-15 Immunex Corp Menschliche tslp nukleinsäuren und polypeptide
DK1417231T3 (da) 2001-07-23 2013-07-22 Immunex Corp Modificeret human thymisk stromal lymphopoietin
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
AU2008287426B2 (en) * 2007-08-10 2014-06-26 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
EP2250199B1 (en) * 2008-02-07 2015-09-02 Merck Sharp & Dohme Corp. Engineered anti-tslpr antibodies
AR082163A1 (es) * 2010-07-15 2012-11-14 Hoffmann La Roche Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
KR101221649B1 (ko) * 2010-11-01 2013-01-14 광주과학기술원 알러지 질환의 예방 또는 치료용 약제학적 조성물, 그의 스크리닝 방법
SG11201600935SA (en) * 2013-08-09 2016-03-30 Astellas Pharma Inc Novel anti-human tslp receptor antibody
BR112016025852B1 (pt) 2014-05-07 2022-11-01 Amgen Inc Dispositivo de injeção para aplicação de fármaco
MX2016014761A (es) 2014-05-16 2017-05-25 Amgen Inc Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2).
JP6817074B2 (ja) 2014-06-03 2021-01-20 アムジエン・インコーポレーテツド 制御可能な薬物送達システム及び使用方法
EP3206739B1 (en) 2014-10-14 2021-12-01 Amgen Inc. Drug injection device with visual and audio indicators
CN114569716A (zh) 2014-10-23 2022-06-03 美国安进公司 降低药物制剂的粘度
EP3689394A1 (en) 2014-12-19 2020-08-05 Amgen Inc. Drug delivery device with live button or user interface field
WO2016133947A1 (en) 2015-02-17 2016-08-25 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
EP3981450A1 (en) 2015-02-27 2022-04-13 Amgen, Inc Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
MA55472A (fr) 2015-09-09 2022-02-09 Novartis Ag Molécules de liaison de lymphopoïétine stromale thymique (tslp) et procédés d'utilisation des molécules
MY186352A (en) 2015-09-09 2021-07-15 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
ES2755717T3 (es) 2015-12-09 2020-04-23 Amgen Inc Autoinyector con tapa de señalización
TWI836745B (zh) 2015-12-18 2024-03-21 美商上游生物公司 含有抗人類tslp受體抗體之醫藥組成物
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
DK3429663T3 (da) 2016-03-15 2020-09-28 Amgen Inc Reduktion af sandsynligheden for glasbrud i anordninger til indgivelse af lægemidler
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
US10988284B2 (en) 2016-05-13 2021-04-27 Amgen Inc. Vial sleeve assembly
EP3458988B1 (en) 2016-05-16 2023-10-18 Amgen Inc. Data encryption in medical devices with limited computational capability
EP3465124A1 (en) 2016-06-03 2019-04-10 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
EP3478342A1 (en) 2016-07-01 2019-05-08 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
EP3532127A1 (en) 2016-10-25 2019-09-04 Amgen Inc. On-body injector
US20190358411A1 (en) 2017-01-17 2019-11-28 Amgen Inc. Injection devices and related methods of use and assembly
JP7064501B2 (ja) 2017-02-17 2022-05-10 アムジエン・インコーポレーテツド 無菌流体流路を備える薬物送達デバイスおよび関連する組立方法
CA3052204A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Insertion mechanism for drug delivery device
EP3592403A1 (en) 2017-03-06 2020-01-15 Amgen Inc. Drug delivery device with activation prevention feature
US11571511B2 (en) 2017-03-07 2023-02-07 Amgen Inc. Insertion mechanism and method of inserting a needle of a drug delivery device
KR102619150B1 (ko) 2017-03-09 2023-12-27 암겐 인코포레이티드 약물 전달 장치용 삽입 메커니즘
CA3052676A1 (en) 2017-03-28 2018-10-04 Amgen Inc. Plunger rod and syringe assembly system and method
WO2018201064A1 (en) 2017-04-28 2018-11-01 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
MX2019014615A (es) 2017-06-08 2020-02-07 Amgen Inc Dispositivo de administracion de farmacos accionado por par de torsion.
EP3634539A1 (en) 2017-06-08 2020-04-15 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
AU2018288604B2 (en) 2017-06-22 2023-12-21 Amgen Inc. Device activation impact/shock reduction
WO2018237225A1 (en) 2017-06-23 2018-12-27 Amgen Inc. ELECTRONIC DRUG DELIVERY DEVICE COMPRISING A CAP ACTIVATED BY A SWITCH ASSEMBLY
IL270784B2 (en) 2017-07-14 2023-11-01 Amgen Inc Needle insertion-extraction system with a double torsion spring system
WO2019018169A1 (en) 2017-07-21 2019-01-24 Amgen Inc. PERMEABLE GAS SEALING ELEMENT FOR MEDICINE CONTAINER AND METHODS OF ASSEMBLY
EP3658203B1 (en) 2017-07-25 2022-08-31 Amgen Inc. Drug delivery device with gear module and related method of assembly
JP7242562B2 (ja) 2017-07-25 2023-03-20 アムジエン・インコーポレーテツド 容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法
AU2018309027A1 (en) 2017-08-01 2020-01-16 Amgen Inc. Systems and methods for real time preparation of a polypeptide sample for analysis with mass spectrometry
SG11202000785VA (en) 2017-08-01 2020-02-27 Amgen Inc Systems and methods for performing a real-time glycan assay of a sample
US20200164155A1 (en) 2017-08-09 2020-05-28 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
WO2019036181A1 (en) 2017-08-18 2019-02-21 Amgen Inc. BODY INJECTOR WITH STERILE ADHESIVE PATCH
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
EP3691717B1 (en) 2017-10-04 2023-02-08 Amgen Inc. Flow adapter for drug delivery device
IL272636B2 (en) 2017-10-06 2024-10-01 Amgen Inc Drug delivery device with combination assembly and related assembly method
MA50348A (fr) 2017-10-09 2020-08-19 Amgen Inc Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
MA50527A (fr) 2017-11-03 2020-09-09 Amgen Inc Système et approches pour stériliser un dispositif d'administration de médicament
EP3706830B1 (en) 2017-11-06 2024-08-07 Amgen Inc. Drug delivery device with placement and flow sensing
EP3707075A1 (en) 2017-11-06 2020-09-16 Amgen Inc. Fill-finish assemblies and related methods
US11191904B2 (en) 2017-11-10 2021-12-07 Amgen Inc. Plungers for drug delivery devices
JP7370969B2 (ja) 2017-11-16 2023-10-30 アムジエン・インコーポレーテツド 薬物送達デバイスの扉ラッチ機構
WO2019178151A1 (en) 2018-03-13 2019-09-19 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
MA52015A (fr) 2018-03-13 2021-01-20 Amgen Inc Digestion séquentielle de polypeptides pour une analyse par spectrométrie de masse
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
KR102682705B1 (ko) * 2018-07-04 2024-07-05 고려대학교 세종산학협력단 옥사졸로퀴놀리논 유도체를 유효성분으로 포함하는 우울증 및 스트레스 관련 질환의 예방 또는 치료용 약학 조성물
EP3826701A1 (en) 2018-07-24 2021-06-02 Amgen Inc. Delivery devices for administering drugs
US12115360B2 (en) 2018-07-24 2024-10-15 Amgen Inc. Hybrid drug delivery devices with grip portion
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
WO2020023451A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
CA3103105A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Fluid path assembly for a drug delivery device
WO2020068623A1 (en) 2018-09-24 2020-04-02 Amgen Inc. Interventional dosing systems and methods
WO2020068476A1 (en) 2018-09-28 2020-04-02 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
CN112805048B (zh) 2018-10-02 2023-09-22 安进公司 具有内部力传递的用于药物递送的注射系统
MA53818A (fr) 2018-10-05 2022-01-12 Amgen Inc Dispositif d'administration de médicament ayant un indicateur de dose
IL281894B1 (en) 2018-10-15 2024-08-01 Amgen Inc A drug delivery device with a suppression mechanism
SG11202101824VA (en) 2018-10-15 2021-03-30 Amgen Inc Platform assembly process for drug delivery device
US11213620B2 (en) 2018-11-01 2022-01-04 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
AU2019370159A1 (en) 2018-11-01 2021-04-22 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
EP3894839A1 (en) 2018-12-14 2021-10-20 Amgen Inc. System suitability method for use with protein concentration determination by slope
AU2020221372A1 (en) 2019-02-14 2021-08-19 Amgen Inc. Systems and methods for preparing a sample and performing a real-time assay of the sample
US20220137010A1 (en) 2019-02-20 2022-05-05 Amgen Inc. Methods of determining protein stability
MX2021010414A (es) 2019-03-04 2021-09-14 Amgen Inc Reversibilidad in vivo de especies de alto peso molecular.
WO2020198538A1 (en) 2019-03-27 2020-10-01 Amgen Inc. Methods of fingerprinting therapeutic proteins via a two-dimensional (2d) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products
JP7510952B2 (ja) 2019-04-24 2024-07-04 アムジエン・インコーポレーテツド シリンジ滅菌確認アセンブリ及び方法
KR20220016897A (ko) 2019-06-04 2022-02-10 지앙수 헨그루이 메디슨 컴퍼니 리미티드 흉선 기질 림포포이에틴에 결합할 수 있는 항체 및 이의 용도
AU2020288652A1 (en) 2019-06-05 2021-11-18 Amgen Inc. Methods of identifying attributes of therapeutic proteins
CA3148261A1 (en) 2019-08-23 2021-03-04 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
CN111171150B (zh) * 2020-02-05 2020-12-08 北京智仁美博生物科技有限公司 抗人tslp抗体及其用途
JP2023543167A (ja) 2020-09-18 2023-10-13 アムジエン・インコーポレーテツド ペプチドマッピング分析のための試料を処理する方法
US20240010672A1 (en) 2020-11-05 2024-01-11 Amgen Inc. Materials and methods for protein processing
KR20240011135A (ko) 2021-05-21 2024-01-25 암젠 인크 약물 용기를 위한 충전 레시피를 최적화하는 방법
EP4430174A1 (en) 2021-11-09 2024-09-18 Amgen Inc. Production of therapeutic proteins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE490980T1 (de) 1998-03-19 2010-12-15 Human Genome Sciences Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
WO2002000723A2 (en) 2000-06-28 2002-01-03 Whitehead Institute For Biomedical Research Thymic stromal lymphopoietin receptor molecules and uses thereof
WO2002000724A2 (en) * 2000-06-28 2002-01-03 Amgen, Inc. Thymic stromal lymphopoietin receptor molecules and uses thereof
US6890734B2 (en) 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
WO2003065985A2 (en) * 2002-02-01 2003-08-14 Schering Corporation Uses of mammalian cytokine; related reagents
PL1651247T3 (pl) * 2003-07-18 2009-04-30 Schering Corp Leczeni i diagnozowanie nowotworów przy użyciu limfopoetyny zrębu grasicy
US20050249712A1 (en) * 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
WO2006023791A2 (en) * 2004-08-20 2006-03-02 Amgen Inc. Methods and compositions for treating allergic inflammation
US20060171943A1 (en) 2005-02-01 2006-08-03 Amgen Inc. Compositions and methods of treating fibrotic disorders
JP5258578B2 (ja) * 2006-01-13 2013-08-07 アイアールエム・リミテッド・ライアビリティ・カンパニー アレルギー性疾患を処置するための胸腺間質性リンホポエチン受容体に対する抗体
EP2250199B1 (en) 2008-02-07 2015-09-02 Merck Sharp & Dohme Corp. Engineered anti-tslpr antibodies

Also Published As

Publication number Publication date
TN2009000529A1 (en) 2011-03-31
EP2170957A1 (en) 2010-04-07
ZA200908711B (en) 2010-08-25
WO2008155365A1 (en) 2008-12-24
PE20090768A1 (es) 2009-07-09
US8101182B2 (en) 2012-01-24
JP2010530233A (ja) 2010-09-09
KR20100034015A (ko) 2010-03-31
CA2691157A1 (en) 2008-12-24
TW200918557A (en) 2009-05-01
BRPI0813725A2 (pt) 2014-12-30
CN102027012A (zh) 2011-04-20
AR067045A1 (es) 2009-09-30
CL2008001826A1 (es) 2009-02-20
EA201000006A1 (ru) 2010-10-29
CR11152A (es) 2010-01-20
AU2008265128A1 (en) 2008-12-24
IL202573A0 (en) 2011-08-01
US20090074747A1 (en) 2009-03-19
ECSP099812A (es) 2010-01-29

Similar Documents

Publication Publication Date Title
CO6251325A2 (es) Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr)
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
PE20110668A1 (es) Anticuerpos anti-linfopoyetina estromal timica (anti-tslp)
CR11030A (es) Proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos, que se unen especificamente a cd154 y sus usos
PE20140882A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
PE20110306A1 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3)
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
PE20120340A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
AR083747A1 (es) Anticuerpos anti-il-23
AR072985A1 (es) Tratamiento para una enfermedad autoinmune o trastorno inflamatorio, procedimiento, anticuerpo, proteina de union
CR20130351A (es) Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina (diviisional 9819)
AR063090A1 (es) Proteinas de union al antigeno del receptor de la il-17
PE20120427A1 (es) Anticuerpos contra el receptor de cgrp humano
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
NZ717847A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
ES2572177T3 (es) Anticuerpos neutralizantes anti-B7RP1 humanos
PE20120429A1 (es) Proteinas de enlace de miostatina
EA201390146A1 (ru) Антитела к матриксной металлопротеиназе 9
AR095432A1 (es) Proteínas de unión a antígeno
RS54113B1 (en) COMPOSITIONS AND PROCEDURES FOR ANTIBODIES ON THE C5 COMPLEMENTARY PROTEIN
PE20121361A1 (es) Antagonistas de pcsk9
PE20120414A1 (es) Proteinas biespecificas tetravalentes de union a antigeno
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20120306A1 (es) Anticuerpos anti-egfr y vectores que los codifican
PE20150222A1 (es) Anticuerpos multiespecificos

Legal Events

Date Code Title Description
FA Application withdrawn